EUVIMEDEUVIMED entdecken
Crossref

Eculizumab as a new option for perioperative treatment in thymoma-associated myasthenia gravis

Hui Wu, Xianglin Chu, Huahua Zhong, Ying Huang, Hongxia Yang, Guoyan Qi, Lei Jin, Ran Chen, Wenji Jia, Ji Xiong, Liewen Pang, Chongbo Zhao und 2 weitere

Clinical Immunology · 2026-02 · 283 · 110657

DOI: 10.1016/j.clim.2025.110657 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Immunology, 2026-02. Verfasst von Hui Wu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fuda…. Hauptthemen laut MEDLINE: Myasthenia Gravis, Antibodies, Monoclonal, Humanized, Thymoma, Thymus Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Key Technologies Research and Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The efficacy of eculizumab as a perioperative treatment in patients with thymoma-associated myasthenia gravis (TAMG) has not been evaluated. This prospective study included patients with TAMG who received standard-of-care therapy (Soc group, n = 20) or combined with eculizumab (Ecu group, n = 13). At 1 week, the Ecu group showed a marked improvement compared to the Soc group, as evidenced by a reduction in Quantitative Myasthenia Gravis (QMG) (7.39 ± 3.47 vs 0.25 ± 5.13, P = 0.0001), Manual Muscle Test (MMT) (6.39 ± 4.66 vs 0.15 ± 3.96, P = 0.0003), and MG Activities of Daily Living (MG-ADL) (4.85 ± 3.16 vs 0.30 ± 3.47, P = 0.0006). No significant differences were observed in operative time, or intraoperative blood loss. The rate of postoperative myasthenic crisis was 9.1 % (1/13) in the Ecu group, compared to 20 % (4/20) in the Soc group (P = 0.33). This study highlights the role of eculizumab in TAMG as a rapid symptom-control treatment before thymomectomy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisAntibodies, Monoclonal, HumanizedThymomaThymus NeoplasmsHumansFemaleMaleMiddle AgedAdultAgedProspective StudiesPerioperative CareTreatment OutcomeComplement Inactivating Agents

Stichwörter der Autor:innen

EculizumabPerioperative managementRapid controlThymoma-associated myasthenia gravis

Substanzen

eculizumabAntibodies, Monoclonal, HumanizedComplement Inactivating Agents

Autor:innen und Institutionen

  • Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai 200040, China; Department of Neurology, Jing'an…
  • Department of Cardiothoracic Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
  • Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai 200040, China.
  • Department of Neurology, Shenzhen People's Hospital, the second Clinical Medical College of Jinan University, Shenzhen 518020, China.
  • Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China.
  • Department of Neurology, No.2 Affiliated Hospital, Kunming Medical University, Kunming 650101, China.

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Key Technologies Research and Development Program

Zitieren

APA

Wu, H., Chu, X., Zhong, H., Huang, Y., Yang, H., Qi, G., Jin, L., Chen, R., Jia, W., Xiong, J., Pang, L., Zhao, C., Song, J., & Luo, S. (2026). Eculizumab as a new option for perioperative treatment in thymoma-associated myasthenia gravis. Clinical Immunology, 283, 110657. https://doi.org/10.1016/j.clim.2025.110657

Vancouver

Wu H, Chu X, Zhong H, Huang Y, Yang H, Qi G, et al. Eculizumab as a new option for perioperative treatment in thymoma-associated myasthenia gravis. Clinical Immunology. 2026;283:110657. doi:10.1016/j.clim.2025.110657

BibTeX
@article{Wu2026,
  author = {Wu, Hui and Chu, Xianglin and Zhong, Huahua and Huang, Ying and Yang, Hongxia and Qi, Guoyan and Jin, Lei and Chen, Ran and Jia, Wenji and Xiong, Ji and Pang, Liewen and Zhao, Chongbo and Song, Jie and Luo, Sushan},
  title = {Eculizumab as a new option for perioperative treatment in thymoma-associated myasthenia gravis},
  journal = {Clinical Immunology},
  year = {2026},
  volume = {283},
  pages = {110657},
  doi = {10.1016/j.clim.2025.110657}
}
Kostenlos starten →